secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001213900-23-053035
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive receives FDA request for additional data on LDC NDA; timeline extended
--------------------------------------------------------------------------------

- FDA asked for risk assessment and clinical data to evaluate tolerability of lanthanum dioxycarbonate in dialysis patients.
- Pre-NDA meeting revealed quantitative differences in GI adverse findings between LDC and lanthanum carbonate.
- Company plans follow-up meeting with FDA and expects further updates in Q3 2023.
- Bioequivalence to Fosrenol was previously established in Phase I studies; no GI neoplasms seen in mouse study.
- LDC targets hyperphosphatemia in CKD dialysis patients; global market opportunity >$2.5B in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023053035/0001213900-23-053035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023053035/ea181168-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-053035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer